Concepts (100)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hydromorphone | 1 | 2024 | 3 | 0.890 |
Why?
|
| Pneumonia, Ventilator-Associated | 3 | 2013 | 36 | 0.840 |
Why?
|
| Fentanyl | 1 | 2024 | 66 | 0.830 |
Why?
|
| Respiration, Artificial | 2 | 2024 | 298 | 0.740 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 527 | 0.610 |
Why?
|
| Pharmacy Service, Hospital | 2 | 2019 | 21 | 0.560 |
Why?
|
| Students, Pharmacy | 1 | 2014 | 12 | 0.410 |
Why?
|
| Medication Reconciliation | 1 | 2014 | 14 | 0.410 |
Why?
|
| Pharmacists | 2 | 2018 | 130 | 0.400 |
Why?
|
| Pneumonia, Bacterial | 1 | 2013 | 90 | 0.360 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2012 | 60 | 0.360 |
Why?
|
| Bacterial Infections | 1 | 2012 | 150 | 0.340 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2020 | 126 | 0.250 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 801 | 0.240 |
Why?
|
| Intensive Care Units | 3 | 2024 | 420 | 0.210 |
Why?
|
| Critical Illness | 4 | 2020 | 330 | 0.190 |
Why?
|
| Hypnotics and Sedatives | 2 | 2020 | 66 | 0.160 |
Why?
|
| Tachycardia | 1 | 2020 | 28 | 0.160 |
Why?
|
| Dexmedetomidine | 1 | 2020 | 10 | 0.160 |
Why?
|
| Cross Infection | 2 | 2012 | 164 | 0.150 |
Why?
|
| Pharmacy Residencies | 1 | 2019 | 1 | 0.150 |
Why?
|
| Cohort Studies | 1 | 2024 | 2620 | 0.140 |
Why?
|
| Aged | 6 | 2024 | 14965 | 0.140 |
Why?
|
| Blood Coagulation Factors | 1 | 2018 | 15 | 0.140 |
Why?
|
| Plasma | 1 | 2018 | 38 | 0.130 |
Why?
|
| Periodicals as Topic | 1 | 2019 | 178 | 0.120 |
Why?
|
| Warfarin | 1 | 2018 | 125 | 0.120 |
Why?
|
| Retrospective Studies | 3 | 2024 | 6872 | 0.120 |
Why?
|
| Middle Aged | 5 | 2024 | 18273 | 0.120 |
Why?
|
| Benzodiazepines | 1 | 2016 | 107 | 0.120 |
Why?
|
| Hemorrhage | 1 | 2018 | 286 | 0.120 |
Why?
|
| Critical Care | 1 | 2019 | 402 | 0.110 |
Why?
|
| Humans | 11 | 2024 | 65140 | 0.110 |
Why?
|
| Hypertension | 1 | 2020 | 612 | 0.110 |
Why?
|
| Male | 7 | 2024 | 31047 | 0.110 |
Why?
|
| General Practice | 1 | 2014 | 16 | 0.100 |
Why?
|
| Female | 7 | 2024 | 34018 | 0.100 |
Why?
|
| Anticoagulants | 1 | 2018 | 525 | 0.100 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2013 | 51 | 0.100 |
Why?
|
| Nurses | 1 | 2014 | 110 | 0.090 |
Why?
|
| Immunocompromised Host | 1 | 2012 | 103 | 0.090 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2012 | 206 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 1559 | 0.090 |
Why?
|
| Long-Term Care | 1 | 2012 | 179 | 0.090 |
Why?
|
| Infection Control | 1 | 2012 | 103 | 0.080 |
Why?
|
| Anti-Ulcer Agents | 1 | 2010 | 8 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 460 | 0.080 |
Why?
|
| Histamine H2 Antagonists | 1 | 2010 | 17 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 991 | 0.080 |
Why?
|
| Proton Pump Inhibitors | 1 | 2010 | 47 | 0.080 |
Why?
|
| Anesthetics, Intravenous | 1 | 2009 | 25 | 0.080 |
Why?
|
| Propofol | 1 | 2009 | 21 | 0.080 |
Why?
|
| Clostridium Infections | 1 | 2010 | 49 | 0.070 |
Why?
|
| Risk Factors | 3 | 2020 | 5429 | 0.070 |
Why?
|
| Age Factors | 1 | 2012 | 1586 | 0.070 |
Why?
|
| Physicians | 1 | 2014 | 474 | 0.070 |
Why?
|
| Time Factors | 2 | 2012 | 3762 | 0.070 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 5614 | 0.070 |
Why?
|
| Hospitalization | 1 | 2014 | 1392 | 0.060 |
Why?
|
| Incidence | 1 | 2009 | 1419 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2020 | 1141 | 0.050 |
Why?
|
| Adult | 3 | 2016 | 17358 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 856 | 0.040 |
Why?
|
| Length of Stay | 2 | 2016 | 828 | 0.040 |
Why?
|
| Education, Pharmacy | 1 | 2019 | 17 | 0.040 |
Why?
|
| Mentors | 1 | 2019 | 118 | 0.040 |
Why?
|
| International Normalized Ratio | 1 | 2018 | 36 | 0.030 |
Why?
|
| Pharmaceutical Services | 1 | 2018 | 33 | 0.030 |
Why?
|
| Professional Role | 1 | 2018 | 45 | 0.030 |
Why?
|
| Lorazepam | 1 | 2016 | 8 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 296 | 0.030 |
Why?
|
| Internet | 1 | 2019 | 467 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2016 | 137 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 587 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2018 | 335 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2010 | 3308 | 0.020 |
Why?
|
| Synbiotics | 1 | 2012 | 5 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 2701 | 0.020 |
Why?
|
| Oral Hygiene | 1 | 2012 | 14 | 0.020 |
Why?
|
| Hand Disinfection | 1 | 2012 | 18 | 0.020 |
Why?
|
| Chlorhexidine | 1 | 2012 | 17 | 0.020 |
Why?
|
| Ventilator Weaning | 1 | 2012 | 21 | 0.020 |
Why?
|
| Gastrointestinal Agents | 1 | 2012 | 26 | 0.020 |
Why?
|
| Disinfectants | 1 | 2012 | 26 | 0.020 |
Why?
|
| Patient Positioning | 1 | 2012 | 51 | 0.020 |
Why?
|
| Inservice Training | 1 | 2012 | 85 | 0.020 |
Why?
|
| Probiotics | 1 | 2012 | 57 | 0.020 |
Why?
|
| Drainage | 1 | 2012 | 152 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2012 | 317 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2010 | 11 | 0.020 |
Why?
|
| Intubation, Intratracheal | 1 | 2012 | 195 | 0.020 |
Why?
|
| Syndrome | 1 | 2009 | 180 | 0.020 |
Why?
|
| Boston | 1 | 2010 | 258 | 0.020 |
Why?
|
| Propensity Score | 1 | 2010 | 190 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 415 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2009 | 162 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 930 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2009 | 306 | 0.020 |
Why?
|
| Heart Failure | 1 | 2009 | 957 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2012 | 5792 | 0.010 |
Why?
|